🇺🇸 FDA

Intelligence · Clinical Pipeline

PARItec Pipeline

All ClinicalTrials.gov programs at PARItec — phase, modality, and trial IDs.

Programs
84

Quick answer

PARItec has 84 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. -, RIVAROXABAN, RIVAROXABAN

    Pari Pharma GmbH

    newly diagnosed or relapsing deep venous thrombosis related to Behçet’s syndrome

    phase 2 small molecule active

    1 trial

  2. 11C-UCB-J, 18F-DPA-714, [11C]PiB

    Pari Pharma GmbH

    Alzeihmer disease

    phase 2 small molecule active

    1 trial

  3. A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MS

    Pari Pharma GmbH

    Multiple sclerosis

    phase 2 other active

    1 trial

  4. ADALIMUMAB, USTEKINUMAB , ADALIMUMAB , USTEKINUMAB, Olumiant 4 mg film-coated tablets

    Pari Pharma GmbH

    Folliculitis decalvans

    phase 2 small molecule active

    1 trial

  5. AMGLIDIA 6 mg/mL oral suspension

    Pari Pharma GmbH

    Transient hyperglycaemia in premature infants

    phase 2 small molecule active

    1 trial

  6. AMPHOTERICIN B , VANCOMYCIN , Gentamicin_APHP

    Pari Pharma GmbH

    Healthy volunteers : Healthy adults with no history of gastrointestinal disease Patients with IBD in remission

    phase 2 small molecule active

    1 trial

  7. ARTEGENE

    Pari Pharma GmbH

    Severe Combined Immuno-Deficiency (SCID) caused by biallelic mutations in the Artemis gene (DCLRE1C)

    phase 2 small molecule active

    1 trial

  8. Air médical en bouteille, OXYGEN

    Pari Pharma GmbH

    Alternating Hemiplegia of Childhood

    phase 2 small molecule active

    1 trial

  9. Allogeneic Mesenchymal stromal cells derived from adipose tissue thawed and cultured

    Pari Pharma GmbH

    Adults diagnosed with SJS-TEN with at least 10% of body surface area involved

    phase 2 small molecule active

    1 trial

  10. Arvisol placebo, Arvisol 150mg

    Pari Pharma GmbH

    Patients with severe Alcohol Use Disorder (according to DSM 5) at entry of a scheduled inpatient alcohol cessation attempt

    phase 2 small molecule active

    1 trial

  11. Atomoxetin STADA 40 mg Hartkapseln, GELATIN

    Pari Pharma GmbH

    Healthy subjects with no neurological or psychiatric disorders

    phase 2 small molecule active

    1 trial

  12. BARICITINIB

    Pari Pharma GmbH

    Juvenile Dermatomyositis

    phase 2 small molecule active

    1 trial

  13. BEVACIZUMAB

    Pari Pharma GmbH

    Adult patients with persistent dyspnea more than 3 months after acute COVID-19 infection.

    phase 2 small molecule active

    1 trial

  14. BEVACIZUMAB, ATEZOLIZUMAB

    Pari Pharma GmbH

    liver transplanted patients with advanced hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  15. Benlysta 200 mg solution for injection in pre-filled syringe., Placebo of belimumab

    Pari Pharma GmbH

    Cryoglobulinemia vasculitis

    phase 2 small molecule active

    1 trial

  16. CARBOCAINE 20 mg/ml, solution injectable

    Pari Pharma GmbH

    Ischemic stroke

    phase 2 small molecule active

    1 trial

  17. CEFAZOLIN, CLOXACILLIN, CLAVULANIC ACID, AMOXICILLIN, AMOXICILLIN

    Pari Pharma GmbH

    acute osteomyelitis of the child

    phase 2 small molecule active

    1 trial

  18. CEFEPIME , AMIKACIN , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

    Pari Pharma GmbH

    gram-negative bacillus pneumonia acquired during mechanical ventilation in patients receiving Extracorporeal Membrane veno-arterial oxygenation

    phase 2 small molecule active

    1 trial

  19. CLAIRYG 50 mg/ml, solution pour perfusion, MESNA EG 100 mg/ml, solution injectable pour perfusion, CYCLOPHOSPHAMIDE SANDOZ 1000 mg, poudre pour solution injectable ou pour perfusion, SOLUMEDROL 1 g, poudre et solvant pour solution injectable

    Pari Pharma GmbH

    paraneoplastic sensory neuropathy with anti-Hu antibodies

    phase 2 small molecule active

    1 trial

  20. CYTARABINE, SULFASALAZINE, IDARUBICIN HYDROCHLORIDE

    Pari Pharma GmbH

    Recently diagnosed non favorable Acute Myeloid Leukemias

    phase 2 small molecule active

    1 trial

  21. Cell therapy for Inclusion Body Myositis (IBM) by muscle injection of autologous uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF): a phase I trial

    Pari Pharma GmbH

    Inclusion Body Myositis

    phase 2 other active

    1 trial

  22. DEXAMETHASONE, CARFILZOMIB, DEXAMETHASONE, DEXAMETHASONE, CC-92480

    Pari Pharma GmbH

    Patients with relapsed/refractory symptomatic multiple myeloma (MM)

    phase 2 small molecule active

    1 trial

  23. DIMETHYL FUMARATE, DIMETHYL FUMARATE

    Pari Pharma GmbH

    Macular degeneration

    phase 2 small molecule active

    1 trial

  24. DONEPEZIL ARROW 5 mg, comprimé pelliculé, The placebo has the same container composition as the investigational medicinal product (exception of the active substance) and is manufactured by the same manufacturer (pui of the brest university hospital) according to the same procedures as the investigational medicinal product. the active substance is lactose monohydrate, ARICEPT 5 mg, comprimé pelliculé, DONEPEZIL BIOGARAN 5 mg, comprimé pelliculé

    Pari Pharma GmbH

    Anorexia nervosa

    phase 2 small molecule active

    1 trial

  25. Dream01, IMATINIB

    Pari Pharma GmbH

    SCD severe patients

    phase 2 small molecule active

    1 trial

  26. Enema transplant of fecal microbiota 25g/100mL

    Pari Pharma GmbH

    Austistic spectrum disorder

    phase 2 small molecule active

    1 trial

  27. Enema transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  28. Epidyolex 100 mg/ml oral solution

    Pari Pharma GmbH

    Children and adolescents with severe neurodevelopmental disorders

    phase 2 small molecule active

    1 trial

  29. FEBUXOSTAT, ALLOPURINOL

    Pari Pharma GmbH

    Gout adult patients

    phase 2 small molecule active

    1 trial

  30. FORTRANS, poudre pour solution buvable en sachet., TOXICARB, suspension buvable

    Pari Pharma GmbH

    Major patients intoxicated by functional toxicant(s), hospitalized in intensive care and intubated.

    phase 2 small molecule active

    1 trial

  31. First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression (TEMOTRAD01)

    Pari Pharma GmbH

    Adults with non-contrast-enhancing diffuse brainstem gliomas with non-threatening infiltrative clinical and/or radiological progression, Adult brain stem gliomas

    phase 2 other active

    1 trial

  32. GADOTERIC ACID, [18F]fludarabine

    Pari Pharma GmbH

    Patients with newly diagnosed primary central nervous system lymphoma naïve to surgery, radiotherapy or chemotherapy

    phase 2 small molecule active

    1 trial

  33. GLUCOSE 5 % B.BRAUN, solution pour perfusion, ZIMINO 2,5 mg/ml, solution à diluer pour perfusion

    Pari Pharma GmbH

    subarachnoid hemorrhages of aneurysmal origin (HSAa)

    phase 2 small molecule active

    1 trial

  34. GRAALL2014

    Pari Pharma GmbH

    Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)

    phase 2 other active

    1 trial

  35. Gazyvaro 1,000 mg concentrate for solution for infusion.

    Pari Pharma GmbH

    Non-infectious active cryoglobulinemia vasculitis who are either refractory or intolerant to Rituximab

    phase 2 small molecule active

    1 trial

  36. Gazyvaro 1,000 mg concentrate for solution for infusion.

    Pari Pharma GmbH

    PR3-ANCA granulomatosis with polyangiitis (Wegener’s)

    phase 2 small molecule active

    1 trial

  37. ILT-101 liquide, Placebo of ILT-101

    Pari Pharma GmbH

    Autism Spectrum disorder ASD

    phase 2 small molecule active

    1 trial

  38. ILT-101 liquide, Placebo of ILT-101, CICLOSPORIN

    Pari Pharma GmbH

    Patient with newly diagnosed (≤ 3 months) type 1 diabetes stage 3

    phase 2 small molecule active

    1 trial

  39. IMFINZI 50 mg/mL concentrate for solution for infusion., TREMELIMUMAB

    Pari Pharma GmbH

    Hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  40. INFLIXIMAB , TOCILIZUMAB , Cosentyx 300 mg solution for injection in pre-filled pen, ADALIMUMAB

    Pari Pharma GmbH

    TAkayasu ARteritiS

    phase 2 small molecule active

    1 trial

  41. INFLIXIMAB, RoActemra 20 mg/mL concentrate for solution for infusion

    Pari Pharma GmbH

    Takayasu arteritis

    phase 2 small molecule active

    1 trial

  42. INTERFERON GAMMA , TOCILIZUMAB , DALTEPARIN , HEPARIN , BARICITINIB, FLUDROCORTISONE , HYDROCORTISONE, OCTAPLASLG, solution pour perfusion, BARICITINIB, ANAKINRA , FILGRASTIM

    Pari Pharma GmbH

    Sepsis

    phase 2 small molecule active

    1 trial

  43. ISATUXIMAB

    Pari Pharma GmbH

    Isatuximab in type I cryoglobulinaemia: A prospective pilot study

    phase 2 small molecule active

    1 trial

  44. Itacitinib

    Pari Pharma GmbH

    Adults patients having non severe HLH

    phase 2 small molecule active

    1 trial

  45. Itacitinib, placebo of itacitinib 100mg

    Pari Pharma GmbH

    Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening

    phase 2 small molecule active

    1 trial

  46. Jakavi 15 mg tablets, Jakavi 5 mg tablets, Jakavi 10 mg tablets, Jakavi 20 mg tablets

    Pari Pharma GmbH

    haemophagocytic lymphohistiocytosis (HLH) in children

    phase 2 small molecule active

    1 trial

  47. Jakavi 15 mg tablets, Placebo of Jakavi 15mg

    Pari Pharma GmbH

    Inclusion body Myositis

    phase 2 small molecule active

    1 trial

  48. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Non-resectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does PARItec have?

84 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.